Minimum costs to manufacture new treatments for COVID-19

INTRODUCTION: ‘Repurposing’ existing drugs to treat COVID-19 is vital to reducing mortality and controlling the pandemic. Several promising drugs have been identified and are in various stages of clinical trials globally. If efficacy of these drugs is demonstrated, rapid, mass availability at an aff...

Descripción completa

Detalles Bibliográficos
Autores principales: Hill, Andrew, Wang, Junzheng, Levi, Jacob, Heath, Katie, Fortunak, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mediscript Ltd 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331548/
https://www.ncbi.nlm.nih.gov/pubmed/32405423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331548/
https://www.ncbi.nlm.nih.gov/pubmed/32405423

Ejemplares similares